The prevalence of prolonged QTc and associated risks of starting macrolide treatment

B. Allison (Manchester, United Kingdom), A. Bikov (Manchester, United Kingdom)

Source: International Congress 2022 – Biomarkers and lung function in COPD exacerbation

Session: Biomarkers and lung function in COPD exacerbation
Session type: Thematic Poster
Number: 4050

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Allison (Manchester, United Kingdom), A. Bikov (Manchester, United Kingdom). The prevalence of prolonged QTc and associated risks of starting macrolide treatment. 4050

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.